Modulation of GABA- and Glycine-Activated Ionic Currents with Semax in Isolated Cerebral Neurons
- 26 Downloads
The concentration-clamp experiments with neurons isolated from the rat brain showed that nootropic and neuroprotective drug Semax added to perfusion solution at concentration of 1 μM augmented the amplitude of GABA-activated ionic currents in cerebellum Purkinje cells by 147±13%. In addition, Semax in perfusion solution (0.1 and 1 μM) diminished the amplitude of glycine-activated chloride currents in hippocampal pyramidal neurons down to 68 and 43% control level, respectively. Both potentiating and inhibitory effects developed slowly, and they were poorly reversible, which indicated a probable implication of second messengers in the observed phenomena. Semax accelerated the falling edge of glycine-activated current both after a short-term co-application with agonist and after addition of this peptide into perfusion solution.
Key WordsSemax GABAA receptor glycine receptor cerebellum hippocampus
Unable to display preview. Download preview PDF.
- 1.Ashmarin IP, Nezavibatko VN, Myasoedov NF, Kamensky AA, Grivennikov IA, Ponomareva-Stepnaya MA, Andreeva LA, Kaplan AY, Koshelev VB, Ryasina TV. Nootropic analogue of adrenocorticotropin 4-10-Semax: (the experience of design and investigation over 15 years). Zh. Vyssh. Nervn. Deyat. 1997;47(2):429-430. Russian.Google Scholar
- 2.V’unova TV, Shevchenko KV, Shevchenko VP, Bobrov MYu, Bezuglov VV, Myasoedov NF. Binding of Regulatory Neuropeptide [3H] Semax, Labeled in Terminal Pro, to Plasma Membranes of the Rat Forebrain. Neirokhimiya. 2006;23(1):57-62. Russian.Google Scholar
- 3.Gusev EI, Skvortsova VI, Myasoedov NF, Nezavibat’ko VN, Zhuravleva EYu, Vanichkin AV. Effectiveness of Semax in acute period of hemispheric ischemic stroke (clinical and electrophysiological study). Zh. Nevrol. Psikhiatr. 1997;96(6):26-54. Russian.Google Scholar
- 4.Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh. Nevrol. Psikhiatr. 2005;105(2):35-40.Google Scholar
- 5.Shuvaev AN, Salmin VV, Kuvacheva NV, Pozhilenkova EA, Salmina AB. Modern tendencies in the development of the patchclamp technique: new opportunities for neuropharmacology and neurobiology. Annaly Klin. Eksp. Nevrol. 2015;9(4):54-58. Russian.Google Scholar
- 10.Hiu T, Farzampour Z, Paz JT, Wang EH, Badgely C, Olson A, Micheva KD, Wang G, Lemmens R, Tran KV, Nishiyama Y, Liang X, Hamilton SA, O’Rourke N, Smith SJ, Huguenard JR, Bliss TM, Steinberg GK. Enhanced phasic GABA inhibition during the repair phase of stroke: a novel therapeutic target. Brain. 2016;139(Pt 2):468-480.CrossRefPubMedGoogle Scholar
- 14.Ono Y, Saitow F, Konishi S. Differential modulation of GABAA receptors underlies postsynaptic depolarization- and purinoceptor-mediated enhancement of cerebellar inhibitory transmission: a non-Stationary fluctuation analysis study. PLoS One. 2016;11(3):e0150636. doi: https://doi.org/10.1371/journal.pone.0150636.CrossRefPubMedPubMedCentralGoogle Scholar